Quantitative evaluation of malignant gliomas damage induced by photoactivation of IR700 dye [PDF]
The processes involved in malignant gliomas damage were quantitatively evaluated by microscopy. The near-infrared fluorescent dye IR700 that is conjugated to an anti-CD133 antibody (IR700-CD133) specifically targets malignant gliomas (U87MG) and stem ...
Hideo Higuchi
exaly +5 more sources
Near Infra-Red Photoimmunotherapy with Anti-CEA-IR700 Results in Extensive Tumor Lysis and a Significant Decrease in Tumor Burden in Orthotopic Mouse Models of Pancreatic Cancer [PDF]
Photoimmunotherapy (PIT) of cancer utilizes tumor-specific monoclonal antibodies conjugated to a photosensitizer phthalocyanine dye IR700 which becomes cytotoxic upon irradiation with near infrared light.
Robert Hoffman +2 more
exaly +9 more sources
Recovery of IR700 Fluorescence After Near-Infrared Photoimmunotherapy: Discovery and Mechanistic Insights [PDF]
Background/Objectives: Near-infrared photoimmunotherapy (NIR-PIT) is a molecularly targeted cancer therapy that employs antibody–photoabsorber conjugates (APCs) comprising the photosensitizer IRDye700DX (IR700) and tumor-specific antibodies. Following near-infrared (NIR) light irradiation, IR700 undergoes structural modification, inducing selective and
Hideki Tanaka +2 more
exaly +5 more sources
Urinary IR700 Ligand as an Early Biomarker of Therapeutic Efficacy of Near-Infrared Photoimmunotherapy [PDF]
Near-infrared photoimmunotherapy (NIR-PIT) is a cell-selective cancer therapy employing monoclonal antibody-photoabsorber conjugates (APCs) and near-infrared (NIR) light. When exposed to NIR light, the photoabsorber, IR700, releases an axial ligand, resulting in a transition of the remaining molecule from water-soluble to hydrophobic.
Aki Furusawa +2 more
exaly +5 more sources
Immunomodulatory activity of IR700-labelled affibody targeting HER2 [PDF]
AbstractThere is an urgent need to develop therapeutic approaches that can increase the response rate to immuno-oncology agents. Photoimmunotherapy has recently been shown to generate anti-tumour immunological responses by releasing tumour-associated antigens from ablated tumour cell residues, thereby enhancing antigenicity and adjuvanticity.
Jolanta Saczko +2 more
exaly +6 more sources
PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer [PDF]
Vascular-targeted photodynamic therapy (PDT) is an important strategy for cancer therapy. Conventional vascular-targeted PDT has been achieved by passive photosensitizer (PS) delivery, which involves a high risk of adverse effects.
Lin Wan, Ze Tao, Qing Fan
exaly +4 more sources
Efficacy of EGFR Targeting IR700-Related Photoimmunotherapy in Preventing Growth of Cancer Cells—A Systematic Review [PDF]
Research of Near-Infrared Photoimmunotherapy (NIR-PIT) related to human epidermal growth factor receptor (EGFR) in cancer is very popular in recent years. By destroying the cell membrane, NIR-PIT can kill cancer cells and prevent tumor development.
Junxin Huang +7 more
exaly +4 more sources
MT1-MMP-Targeted Photoimmunotherapy via an IR700-Conjugated Bicyclic Peptide [PDF]
Naoya Kondo, Hirofumi Hanaoka
exaly +3 more sources
Targeted Photo-Induced Elimination of Tumor-Associated Macrophages Suppresses Cancer Progression in a Murine Model. [PDF]
This study demonstrates the selective depletion of tumor‐associated macrophages (TAMs) by targeting CSF1R through near‐infrared photoimmunotherapy (NIR‐PIT). Using a combination of anti‐CSF1R Fab‐IR700 conjugates and localized light irradiation, we achieved tumor suppression and durable antitumor immunity without systemic toxicity.
Nakajima K +6 more
europepmc +2 more sources
Recent advances in near-infrared dye conjugates for near-infrared photoimmunotherapy (NIR-PIT): enhancing therapeutic efficacy and immune mechanisms [PDF]
Near-infrared photoimmunotherapy (NIR-PIT) is an innovative cancer treatment modality that was approved in Japan in 2020 for the treatment of unresectable locally advanced or locally recurrent head and neck cancer.
Yoshikazu Fuse +4 more
doaj +2 more sources

